drugset / Trial / NCT05590598
Efficacy and Safety of Azelastine +Mometasone , Nasal Spray, 140 mcg + 50 mcg, (Sandoz d.d., Slovenia) and Momat Rino Advance, Nasal Spray, 140 mcg + 50 mcg, (Glenmark, India) Administered as a Monotherapy to Patients With Seasonal Allergic Rhinitis.
RandomizedParallel-groupDouble-blindTreatment
Summary
Prospective, multicenter, open, randomized, parallel, clinical study for assessment of comparative efficacy and safety of Azelastine +Mometasone Sandoz (main group) and Momat Rino Advance (control group) administered as a monotherapy to patients with seasonal allergic rhinitis (SAR).
Timeline
- Start
- 2023-02-13
- Primary completion
- 2023-06-14
- Completion
- 2023-06-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Azelastine | Small molecule | 140 ug | Intranasal |
| Background | Mometasone | Other / unclassified | 50 ug | Intranasal |